SCHEMBL560075

SCHEMBL560075

O=C(O)N1CCCC1O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL74963 0.93 HPGD (0.37)
SCHEMBL18639814 0.93 HPGD (0.37)
SCHEMBL4772277 0.91 HPGD (0.37)
SCHEMBL2354161 0.84
SCHEMBL3457559 0.80
SCHEMBL7008319 0.78
SCHEMBL9138450 0.78
SCHEMBL23273394 0.76 POLB (0.38)
SCHEMBL28236930 0.76 POLB (0.38)
SCHEMBL4028231 0.75 HPGD (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023126968-A1 A PROCESS FOR THE SYNTHESIS OF BCX-1777 AND BCX-4430 COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2023-07-06 WO claimed
US-20120035238-A1 COMPOUNDS AND METHODS FOR TREATING CANCER AND VIRAL INFECTIONS GOFF HILL LIMITED (BB) 2012-02-09 US claimed
EP-2142521-A1 INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME Abbott Laboratories (US) 2010-01-13 EP claimed
WO-2008134693-A1 INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME ABBOTT LABORATORIES (US) 2008-11-06 WO claimed
US-12617796-B2 Antagonists of the adenosine A2a receptor JANSSEN PHARMACEUTICA NV (BE) 2026-05-05 US disclosed
US-20240368140-A1 CERTAIN PLADIENOLIDE COMPOUNDS AND METHODS OF USE EISAI R&D MANAGEMENT CO., LTD. (JP) 2024-11-07 US disclosed
US-11926619-B2 Certain pladienolide compounds and methods of use EISAI R & D MANAGEMENT CO., LTD. (JP) 2024-03-12 US disclosed
EP-4225756-A2 AUTOTAXIN INHIBITOR COMPOUNDS Ildong Pharmaceutical Co., Ltd. (KR) 2023-08-16 EP disclosed
US-20230234939-A1 IMIDAZOLE-PYRAZOLE DERIVATIVES AS ANTIBACTERIALS HOFFMANN-LA ROCHE INC. (US) 2023-07-27 US disclosed
WO-2023126968-A1 A PROCESS FOR THE SYNTHESIS OF BCX-1777 AND BCX-4430 COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2023-07-06 WO disclosed
US-20230203041-A1 ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR JANSSEN PHARMACEUTICA NV (BE) 2023-06-29 US disclosed
US-20230141403-A1 NOVEL IMIDAZOPYRAZINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2023-05-11 US disclosed
US-20070043065-A1 Amide derivatives ASTRAZENECA AB (SE) 2007-02-22 US disclosed
WO-2007011284-A1 THERAPEUTIC AGENTS ASTRAZENECA AB (SE) 2007-01-25 WO disclosed
EP-1682520-A1 AMIDE DERIVATIVES AstraZeneca AB (SE) 2006-07-26 EP disclosed
WO-2005042502-A1 AMIDE DERIVATIVES ASTRAZENECA AB (SE) 2005-05-12 WO disclosed
EP-1347990-A2 PEPTIDE MIT INHIBIERENDER AKTIVITÄT ZUR PRODUKTION VON STICKSTOFFMONOXID FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-10-01 EP disclosed
EP-1235938-A2 FLUORESCENT QUENCHING DETECTION REAGENTS AND METHODS Epoch Biosciences, Inc. (US) 2002-09-04 EP disclosed
WO-2002055541-A2 PEPTIDES HAVING INHIBITING ACTIVITY ON THE PRODUCTION OF NITRIC OXIDE FUJISAWA PHARMACEUTICAL CO (JP) 2002-07-18 WO disclosed
WO-2001042505-A2 FLUORESCENT QUENCHING DETECTION REAGENTS AND METHODS EPOCH BIOSCIENCES, INC. (US) 2001-06-14 WO disclosed